LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Trial details
- Registry ID
- NCT06216301
- Drugs studied
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
TrialRedline tracks 7 clinical trials sponsored by NovoCure GmbH: 4 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 | NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy | Recruiting | 2028-10Estimated |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNCT06556563 | Optune® device, Pembrolizumab, Temozolomide | Active not recruiting | 2029-04Estimated |
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).NCT02831959 | Best Standard of Care, NovoTTF-200M device | Completed | 2024-11-29Actual |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)NCT02973789 | Immune checkpoint inhibitors or docetaxel, NovoTTF-200T | Completed | 2024-09-24Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBMNCT04492163 | TTFields | Completed | 2023-06-20Actual |
| LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)NCT06558799 | NovoTTF-200T, Pembrolizumab | Terminated | 2026-02-23Actual |
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung CancerNCT04892472 | NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg | Terminated | 2025-01-10Actual |
Names as written in the registry records.
Before: Recruiting. After: Active not recruiting.
Before: Estimated. After: Actual.
Before: 69 participants (planned). After: 31 participants (actual).
Before: Estimated. After: Actual.
Before: 31 Jan 2026. After: 23 Feb 2026.
Before: Active not recruiting. After: Terminated.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Overall survival of patients treated with TTFields + docetaxel or immune checkpoint inhibitors vs. docetaxel or immune checkpoint inhibitors alone (superiority analysis). After: Measure: Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis).
Before: 276 participants (actual). After: 291 participants (actual).